Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

@article{Nobori1994DeletionsOT,
  title={Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers},
  author={Tsutomu Nobori and Kaoru Miura and David J. Wu and Augusto F. Lois and Kenji Takabayashi and Dennis A. Carson},
  journal={Nature},
  year={1994},
  volume={368},
  pages={753-756}
}
CYTOGENETIC abnormalities of chromosome 9p21 are characteristic of malignant melanomas1,2, gliomas3, lung cancers4 and leukaemias5. From a panel of 46 human malignant cell lines, we localized by positional cloning the most frequently deleted region on 9p21. Sequence analysis of the isolated fragment reveals two open reading frames identical to the recently described complementary DNA for the inhibitor of cyclin-dependent kinase 4 (CDK4) 6. Polymerase chain reaction and Southern blot analysis… Expand
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
TLDR
The results suggest that loss of the CDK4I function may contribute to immortalization of human leukemia cells and play a causative role at least in development of human lymphocytic leukemias. Expand
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
TLDR
The deletion analyses strongly suggest that the p16 gene is a tumor-suppressor gene located in chromosome 9p21 that is involved in development of human lymphoid tumors. Expand
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
TLDR
It is concluded that homozygous p16 gene deletions characterize a subset of ALL with features of aggressive disease. Expand
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
TLDR
Two groups of CDKIs are classified based on the structure of the proteins, including the p15, p16, and p18CDKIs, which have ankyrin repeat motifs, and the p27/Kip1 and p21 CDKI genes, which are rarely mutated in human malignancies. Expand
Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas
TLDR
It is suggested that alterations in the integrity of the human p27 gene are not common events in human breast carcinoma, despite the occurrence of two sequence variations with respect to the reported sequence. Expand
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma
TLDR
Examination of the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors indicates that deletion of P15 and P16 occurs in about 15% of diffuse large- cell NHL and is not usually detected by cytogenetic analysis. Expand
Mutational and methylation analysis of the cyclin‐dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia
TLDR
The results indicate that genetic alterations of p16 gene are rare events in patients with CLL, and the clarification of the role of p 16 gene promoter methylation in the pathogenesis and evolution of CLL needs further investigation. Expand
Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
TLDR
Observations support a role for p15/p16 gene inactivation in bladder carcinogenesis and/or the promotion of cell growth in vitro and lend support to the hypothesis that homozygous deletion centred on 9p21 is a mechanism by which both p15 and p16 genes are co-inactivated. Expand
p16 mutations/deletions are not frequent events in prostate cancer.
TLDR
It is suggested that p16INK4 is a tumour-suppressor gene involved in a wide variety of human cancers, and mutation of the p16ink4 gene is not a frequent genetic alteration implicated in prostate cancer development. Expand
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
TLDR
Although deletion of MTS1/CDKN2 may occur in some PNET cell lines, neither deletion nor mutation of the gene is found in tumors before culture, and the genesis of the human central nervous system PNET does not involve deletion or mutation of this gene. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.
TLDR
Findings suggest that the putative tumor suppressor gene at this locus contributes to the malignant process in lung cancers, as well as other types of human cancer. Expand
p21 is a universal inhibitor of cyclin kinases
TLDR
It is found that over expression of p21 inhibits the activity of each member of the cyclin/CDK family, and this results indicate that p21 may be a universal inhibitor of cyclin kinases. Expand
Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas.
TLDR
It is confirmed that loss of DNA sequences on 9p, particularly the IFN genes, occurs at a significant frequency in gliomas, and may represent an important step in the progression of these tumors. Expand
Homozygous deletions within human chromosome band 9p21 in melanoma.
TLDR
A small critical region of 2-3 megabases on 9p21 in which a putative melanoma tumor-suppressor gene appears likely to reside is identified in which several 9p candidate genes have been eliminated because they are located outside of the homozygously deleted regions. Expand
Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia.
TLDR
The shortest region of overlap of these deletions in the various tumors is mapped to the region between the centromeric end of the IFNA/IFNW gene cluster and the MTAP gene locus. Expand
Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s).
Cutaneous malignant melanoma (CMM) is often familial, but the mode of inheritance and the chromosomal location of melanoma susceptibility locus are controversial. Identification of a 34-year-oldExpand
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
TLDR
P16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein, and inhibits the catalytic activity of theCDK4/cyclin D enzymes. Expand
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.
TLDR
Linkage analysis of Utah kindreds and one Texas kindred with multiple cases of cutaneous malignant melanoma provided evidence that a locus for familial melanoma susceptibility is in the chromosomal region 9p13-p22, previously implicated in homozygous deletions in melanoma tumors. Expand
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals. To identify potential Cdk2 regulators, we haveExpand
Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers.
TLDR
The data suggest that MeSAdo phosphorylase deficiency is frequently found in non-small cell lung cancers and can be exploited in designing enzyme-selective chemotherapy. Expand
...
1
2
...